Last $29.14 USD
Change Today +0.23 / 0.80%
Volume 609.7K
As of 5:20 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Open
$29.11
Previous Close
$28.91
Day High
$29.50
Day Low
$28.24
52 Week High
10/30/13 - $101.00
52 Week Low
07/9/14 - $28.24
Market Cap
859.1M
Average Volume 10 Days
641.9K
EPS TTM
$-2.10
Shares Outstanding
29.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEGERION PHARMACEUTICALS INC (AEGR)

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) and LOJUXTA (lomitapide) hard capsules, an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia. It also has the right to use lomitapide in the field of monotherapy or in combination with other dyslipidemic therapies for treatment of patients with other severe forms of hypercholesterolemia. The company distributes its product directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.with other severe forms of hypercholesterolemia. The company distributes its product directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

250 Employees
Last Reported Date: 05/9/14
Founded in 2005

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $584.2K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $350.0K
President of U.S. & International Commercial ...
Total Annual Compensation: $340.0K
Chief Medical Officer
Total Annual Compensation: $380.0K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2013.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 02:30 PM

Aegerion Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 02:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Marc D. Beer, Chief Executive Officer and Director.

Aegerion Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Operating Cash Flows Guidance for the Second Half of 2014; Revises Revenue Guidance for the Fiscal Year 2014

Aegerion Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company's net product sales were $26,973,000 compared to $1,231,000 a year ago. Loss from operations was $15,374,000 compared to $17,948,000 a year ago. Net loss before provision for income taxes was $15,552,000 compared to $18,142,000 a year ago. Net loss was $15,776,000 or $0.54 per basic and diluted share compared to $18,142,000 or $0.64 per basic and diluted share a year ago. Non-GAAP net loss was $7,253,000 or $0.25 per basic and diluted share compared to $14,564,000 or $0.51 per basic and diluted share a year ago. Cash used in operating activities was approximately $9,300,000 for the first quarter of 2014. The company now anticipates reaching cash-flow positive operations in the second half of the year 2014. The company now expects global net product sales of between $180 million and $200 million for fiscal year 2014, revised from the prior range of between $190 million and $210 million. Operating expenses are to be between $145 million and $155 million for the year 2014.

Aegerion Pharmaceuticals, Inc. to Report Q1, 2014 Results on May 06, 2014

Aegerion Pharmaceuticals, Inc. announced that they will report Q1, 2014 results on May 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $29.14 USD +0.23

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEGR.
View Industry Companies
 

Industry Analysis

AEGR

Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.4x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit www.aegerion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.